Gene therapy startup VectorY has raised more than $37m in an Eli Lilly-backed seed round while AR helmet developer XYZ Reality pulled in over $28m.

Funding

VectorY, a Netherlands-based startup developing gene therapies for muscular and neurodegenerative disorders, closed a €31m ($37.5m) seed round today that included pharmaceutical firm Eli Lilly. The startup’s founding investor, life sciences venture capital firm Forbion, co-led the round with an undisclosed investment firm, and it also featured VC firm BioGeneration Ventures.

XYZ Reality, the UK-headquartered developer of an augmented reality (AR) helmet for use in construction, has completed a £20m ($28.1m) series A round featuring construction firm J Coffey…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn